Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Intellia Therapeutics Inc...

    NASDAQ: NTLA · Real-Time Price · USD
    8.96
    0.65 (7.82%)
    At close: Jun 16, 2025, 3:59 PM
    9.78
    9.21%
    Pre-market: Jun 17, 2025, 07:14 AM EDT

    Intellia Therapeutics Statistics

    Share Statistics

    Intellia Therapeutics has 103.58M shares outstanding. The number of shares has increased by 7.3% in one year.

    Shares Outstanding

    n/a
    		 103.58M

    Shares Change (YoY)

    n/a
    		 7.3%

    Shares Change (QoQ)

    n/a
    		 1.64%

    Owned by Institutions (%)

    n/a
    		 98.3%

    Shares Floating

    n/a
    		 97.48M

    Failed to Deliver (FTD) Shares

    n/a
    		 560

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 31.56M, so 30.47% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 31.56M

    Short % of Shares Out

    n/a
    		 30.47%

    Short % of Float

    n/a
    		 34.68%

    Short Ratio (days to cover)

    n/a
    		 5.14

    Valuation Ratios

    The PE ratio is -2.22 and the forward PE ratio is -2.16. Intellia Therapeutics's PEG ratio is 0.71.

    PE Ratio

    n/a
    		 -2.22

    Forward PE

    n/a
    		 -2.16

    PS Ratio

    n/a
    		 19.91

    Forward PS

    n/a
    		 0.4

    PB Ratio

    n/a
    		 1.32

    P/FCF Ratio

    n/a
    		 -3.25

    PEG Ratio

    n/a
    		 0.71
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Intellia Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 5.77, with a Debt / Equity ratio of 0.24.

    Current Ratio

    n/a
    		 5.77

    Quick Ratio

    n/a
    		 5.77

    Debt / Equity

    n/a
    		 0.24

    Debt / EBITDA

    n/a
    		 -0.4

    Debt / FCF

    n/a
    		 -0.59

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $143,615.38

    Profits Per Employee

    n/a
    		 $-1,287,893.3

    Employee Count

    n/a
    		 403

    Asset Turnover

    n/a
    		 0.05

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -64.4% in the last 52 weeks. The beta is 2.13, so Intellia Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.13

    52-Week Price Change

    n/a
    		 -64.4%

    50-Day Moving Average

    n/a
    		 8.06

    200-Day Moving Average

    n/a
    		 12.6

    Relative Strength Index (RSI)

    n/a
    		 57.1

    Average Volume (20 Days)

    n/a
    		 4,212,879

    Income Statement

    In the last 12 months, Intellia Therapeutics had revenue of 57.88M and earned -519.02M in profits. Earnings per share was -5.25.

    Revenue

    n/a
    		 57.88M

    Gross Profit

    n/a
    		 47.59M

    Operating Income

    n/a
    		 -534.26M

    Net Income

    n/a
    		 -519.02M

    EBITDA

    n/a
    		 -523.98M

    EBIT

    n/a
    		 -534.26M

    Earnings Per Share (EPS)

    n/a
    		 -5.25
    Full Income Statement

    Balance Sheet

    The company has 189.18M in cash and 210.2M in debt, giving a net cash position of -21.02M.

    Cash & Cash Equivalents

    n/a
    		 189.18M

    Total Debt

    n/a
    		 210.2M

    Net Cash

    n/a
    		 -21.02M

    Retained Earnings

    n/a
    		 -2.18B

    Total Assets

    n/a
    		 986.16M

    Working Capital

    n/a
    		 438.8M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -348.88M and capital expenditures -5.78M, giving a free cash flow of -354.66M.

    Operating Cash Flow

    n/a
    		 -348.88M

    Capital Expenditures

    n/a
    		 -5.78M

    Free Cash Flow

    n/a
    		 -354.66M

    FCF Per Share

    n/a
    		 -3.59
    Full Cash Flow Statement

    Margins

    Gross margin is 82.23%, with operating and profit margins of -923.1% and -896.77%.

    Gross Margin

    n/a
    		 82.23%

    Operating Margin

    n/a
    		 -923.1%

    Pretax Margin

    n/a
    		 -896.77%

    Profit Margin

    n/a
    		 -896.77%

    EBITDA Margin

    n/a
    		 -905.33%

    EBIT Margin

    n/a
    		 -923.1%

    FCF Margin

    n/a
    		 -612.78%

    Dividends & Yields

    NTLA does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for NTLA is $40.5, which is 352% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $40.5

    Price Target Difference

    n/a
    		 352%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 20
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -2.27

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist